Abstract:Hepatic insulin resistance is associated with metabolic disorders such as type 2 diabetes (T2D), which often develops after the accumulation of lipids in the liver. In particular, elevated plasma levels of free fatty acids (FFA) are the primary sources of hepatic lipid accumulation that contributes to the development of insulin-resistant states. Interestingly, one gut-derived incretin hormone receptor called glucagon-like peptide 1 (GLP-1) receptor, is highly expressed on human hepatocytes. Although GLP-1-based therapies have shown great benefit in the treatment of T2D with improved glycemic control, they also additionally possess extrapancreatic metabolic actions including that in the liver. Studies have demonstrated that GLP-1 receptor agonist (GLP-1 RA) may reverse the progression of nonalcoholic fatty liver disease (NAFLD), a T2D-related disorder characterized by hepatic lipid accumulation. This suggests GLP-1 RA may be effective treatment options for NAFLD and associated hepatic disorders, but the mechanism behind this is still unknown. In the present study, we investigated the function of GLP-1 signaling in protecting human HepG2 hepatocytes from FFA-related damages. By using high-content analysis (HCA) cellomics techniques, we found that treatment with the GLP-1 RA liraglutide has shown a significant lipid droplets-lowering effect in hepatocytes exposure to high levels of FFAs. Liraglutide also decreased free radical generation and subsequently reduced oxidative stress, thus alleviated FFA induced inflammation. Moreover, activation of AMPK by liraglutide increased insulin sensitivity and improved oxidative stress-induced senescence by inducing Sirt1 pathway. Collectively, our results demonstrated that hepatic GLP-1 signaling may play a crucial role in the regulation of lipid deposits and related disorders in liver. This suggests the potential therapeutic usage of GLP-1 RA-based strategies for patients with T2D who also have NAFLD. Disclosure C. Huang: None. H. Li: None. C. Peng: None. E. Kornelius: None. Y. Yang: None. L. Chiu: None. C. Lin: None. Funding Ministry of Science and Technology of Taiwan (108-2314-B-040-021-MY3)

Liraglutide Suppresses Proliferation and Induces Adipogenic Differentiation of 3T3-L1 Cells Via the Hippo-YAP Signaling Pathway

Liraglutide Modulates Lipid Metabolism Via ZBTB20-LPL Pathway

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

Glucagon-like Peptide 1 Regulates Adipogenesis in 3T3-L1 Preadipocytes

The Akt/FoxO1/p27 Pathway Mediates the Proliferative Action of Liraglutide in Β Cells.

GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis

Liraglutide regulates lipid metabolism via FGF21- LKB1- AMPK- ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice

&Lt;p>liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells Via Wnt Pathway</p>

Liraglutide promotes angiogenesis in adipose tissue via suppression of adipocyte-derived IL-6

Protective Action of Liraglutide in Beta Cells Under Lipotoxic Stress Via PI3K/Akt/FoxO1 Pathway

Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro.

Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation

Glucagon Modulates Proliferation And Differentiation Of Human Adipose Precursors.

Liraglutide Reduces Hepatic Glucolipotoxicity‑induced Liver Cell Apoptosis Through NRF2 Signaling in Zucker Diabetic Fatty Rats

Liraglutide Reduces Lipogenetic Signals in Visceral Adipose of Db/db Mice with AMPK Activation and Akt Suppression

Glucagon-Like Peptide-1 Analog-Mediated Protection Against Cholesterol-Induced Apoptosis Via Mammalian Target Of Rapamycin Activation In Pancreatic Beta Tc-6 Cells

An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.

The Key Role of a Glucagon-Like Peptide-1 Receptor Agonist in Body Fat Redistribution

1751-P: Induction of Sirt1-AMPK Pathway by GLP-1RA Liraglutide Reduces Hepatic Lipid Accumulation and Insulin Resistance

GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning

The Role of a Glucagon-Like Peptide-1 Receptor Agonist in Visceral and Subcutaneous Fat Redistribution